Why publish in Clinical & Translational Radiation Oncology?
🔹ctRO is part of ESTRO
🔹Editorial board with international experts
🔹Open access ensures high visibility for your research 🔹Robust review process
🔹No spam emails 😉
Submit your next paper to ctRO!
#radonc #medtwitter #openaccess

It is a great honor and pleasure for me to be appointed by ESTRO as the new editor-in-chief at Clinical & Translational Radiation Oncology. Big thanks to Pierre Blanchard, MD and DZips started the journal from scratch and brought it to where it is today. Let's continue the journey! #radonc #ESTRO24

Here are the slides from the ORATOR2 trial. Key takeaways (short 🧵)

- RT meets primary endpoint compared to historical control
- OS and PFS significantly better in RT arm.

Well done Alison Tree 💙 excellent presentation of the acute tox results from #PACE C

Donal Hollywood award winner at #ESTRO24
Piet Ost for the STORM trial
Congrats to Thomas Zilli and all contributors 👏

#ESTRO24 Piet Ost presenting outcomes of STORM randomized Ph II of MDT v ENRT for oligorecurrent prostate cancer #pcsm

✅ ENRT ⬆️BRFS, LRFS

MDT a/w 8-fold ⬆️ nodal recurrence 3➡️25%

Omitting PB ⬆️ local recurrences 3-fold (5➡️14%), but also increases GU2+ toxicity

During #ESTRO24 we had my first editorial board meeting as editor in chief of the Green Journal.

Wonderful group of dedicated experts. Very happy to work with them for the radonc community.

Excellent talk by Prof vendrely veronique on the GRECCAR12 trial for #rectalcancer at #ESTRO24 .

Did not go this far but a quick 🏃 Tyler Seibert MD PhD style around the city and it was pretty nice too!

Good way to relax after great #ESTRO24 sessions

Please tweete the good stuff Alison. The room was full 10 minutes prior to the session…

ESTRO prostate cancer is a popular topic, we need bigger rooms…

#ESTRO24

Huge endeavour by ESTRO ESMO - Eur. Oncology to create guidelines for combination of #radiotherapy & new cancer drugs.

Looking forward to full paper. As Dr. David Palma discussed, the toxicity threshold to withhold #radiotherapy (or lower dose) needs to be defined on case by case basis.

No benefit of dose escalation (30Gy/5 vs 20Gy/5) for palliation in locally advanced head and neck cancer ineligible to curative treatment.

Dr Malick from 🇮🇳 at #ESTRO24

15 Posts Not To Miss from APCCC24!
Advanced Prostate Cancer Consensus Conference Pierre Blanchard, MD Neeraj Agarwal, MD, FASCO StevePCa Stacy Loeb, MD Michael Hofman Charles Dariane Sarah Weller Guillaume Grs Dra. María Natalia Gandur Quiroga Declan Murphy Piet Ost Yüksel Ürün
oncodaily.com/58533.html

#APCCC24 #Cancer #OncoDaily #Oncology

Testosterone recovery after stopping ADT – who is at risk for long-term non-recovery? Presented by Pierre Blanchard, MD Gustave Roussy. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/4aVAN1S Advanced Prostate Cancer Consensus Conference

Great to have the opportunity to discuss with my friend Thomas Zilli the current status and future of prostate/mets radiotherapy in #prostatecancer at #APCCC24 .

Thanks Uromigos Tom Powles Brian Rini, MD for the invitation!

• Testosterone recovery after stopping ADT – Who is at risk for long-term non-recovery?- Pierre Blanchard, MD

Advanced Prostate Cancer Consensus Conference silke gillessen OncoAlert Thomas Zilli Daniel Castellano Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Rana McKay Michael Hofman Declan Murphy Neha Vapiwala

As long as the community, which often is medoncs discussing radiopharm, as ‘dose’ we are doomed to not make progress. Pains me this basic rad physics 101 terminology is not even known. Now nuc med, who 100% knows the difference, is saying ‘dose’ to over simplify, when they know

And it’s a wrap! It’s been a wonderful and exciting conference. Thanks silke gillessen aurelius omlin and Advanced Prostate Cancer Consensus Conference !

Let’s meet all in 2026 for #APCCC26

And next year for APCCC Diagnostics led by Ken Herrmann and prof. Stefano Fanti

#APCCC24

Great comments by Daniel E Spratt on PSMA therapy
1. Should be treated as radiation treatment and not drug
2. Activity (not dose) should be adapted to tumor burden to ensure proper efficacy
3. Impact of fractionation needs to be studied
#APCCC24

Brilliant lecture by Michael Hofman on differences between PSMA tracers for diagnostics and therapy in #prostatecancer
1. PSMA11, DCFPyL or PSMA7 likely interchangeable
2. For therapy PSMA617 and I&T: likely radio equivalent
#APCCC24